any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.
18 years of age and older
Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies.
Having expressed their free and informed consent.
Affiliated to a social security scheme
Immune deficiency.
HIV infection.
Curative surgery for chronic urinary tract infection.
Urgent surgery.
Single group
ORAL IMPACT treatment
Dietary supplementthe group of patients will be received a 7-days course of ORAL IMPACT
control
Other interventionno intervention
Rate of major postoperative complications
the number of postoperative complications during this study for each patient
Length of stay in hospital (LOS).
Length of stay in hospital (LOS). durind the participation of each patient
Number of admissions in intensive care setting for severe complications.
Number of admissions in intensive care setting for severe complications after major urological surgery.
Rate of transfusions of red blood cells.
Rate of transfusions of red blood cellsduring hospitalisation and after major urological surgery.
mortality rate
3-month mortality rate
Click on the lead sponsor to view all of their trials.
